CompanyGraphShoulder Innovations, Inc.
SI · NYSE Arca · United States
shoulderinnovations.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionOperating margin is -85.1%, lower than 95% of its Medical Devices peers (median 7.3%)
- FinancialsAltman Z-Score 6.91: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
350.39MUSDvs all stocks (USD)
Revenue (TTM)
47.32MUSDvs all stocks (USD)
52-Week Change
41.56%vs all stocks
Market Capitalization
350.39MUSDvs all stocks (USD)
Enterprise Value
338.55MUSDvs all stocks (USD)
Forward P/E
-10.75xvs Medical Devices peers
Price to Sales (TTM)
7.41xvs Medical Devices peers
Price to Book (MRQ)
2.97xvs Medical Devices peers
Enterprise to Revenue
7.15xvs Medical Devices peers
Enterprise to EBITDA
-14.63xvs Medical Devices peers
Gross Margin
78.26%vs Medical Devices peers
Operating Margin
-85.15%vs Medical Devices peers
Return on Assets (TTM)
-23.75%vs Medical Devices peers
Return on Equity (TTM)
-28.67%vs Medical Devices peers
Revenue (TTM)
47.32MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.46USDUpdated Sep 28, 2026Quarterly Revenue Growth
2.80%vs Medical Devices peers
Gross Profit (TTM)
36.20MUSDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-40.36MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
55.95%vs Medical Devices peers
Operating Cash Flow (TTM)
-28.61MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-40.36MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
47.32MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
11.12MUSDFY2025 · Dec 31, 2025Gross Profit
36.20MUSDFY2025 · Dec 31, 2025Operating Income
-26.30MUSDvs all stocks (USD)
Pre-tax Income
-40.36MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-40.36MUSDFY2025 · Dec 31, 2025EBIT
-40.29MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-23.14MUSDFY2025 · Dec 31, 2025Research & Development
7.73MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
54.77MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
70.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-4.65USDFY2025 · Dec 31, 2025EPS (Diluted)
-4.65USDFY2025 · Dec 31, 2025Basic Shares Outstanding
8.67MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
8.67MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-40.36MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-41.57MUSDFY2025 · Dec 31, 2025Free Cash Flow
-48.97MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
26.87MUSDFY2025 · Dec 31, 2025Interest Paid
1.69MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-40.36MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.21MUSDFY2025 · Dec 31, 2025Stock-based Compensation
996.00KUSDFY2025 · Dec 31, 2025Other Non-cash Items
253.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.30MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.37MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-5.73MUSDFY2025 · Dec 31, 2025Capital Expenditures
-7.41MUSDFY2025 · Dec 31, 2025Purchase of Investments
-119.49MUSDFY2025 · Dec 31, 2025Sale of Investments
31.30MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-95.60MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
143.58MUSDFY2025 · Dec 31, 2025Shares Outstanding
20.82MSharesUpdated Sep 28, 2026Total Cash (MRQ)
0.00USDvs all stocks (USD)
Total Debt (MRQ)
14.85MUSDvs all stocks (USD)
Current Ratio (MRQ)
10.71xvs Medical Devices peers
Book Value per Share (MRQ)
6.00USDUpdated Sep 28, 2026Total Assets
169.91MUSDvs all stocks (USD)
Total Current Assets
157.16MUSDFY2025 · Dec 31, 2025Total Liabilities
29.16MUSDFY2025 · Dec 31, 2025Total Non-current Assets
12.74MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
14.96MUSDFY2025 · Dec 31, 2025Total Current Liabilities
14.20MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
26.87MUSDFY2025 · Dec 31, 2025Other Short-term Investments
97.43MUSDFY2025 · Dec 31, 2025Accounts Receivable
8.27MUSDFY2025 · Dec 31, 2025Inventory
21.59MUSDFY2025 · Dec 31, 2025Accounts Payable
8.87MUSDFY2025 · Dec 31, 2025Short-term Debt
62.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
772.00KUSDFY2025 · Dec 31, 2025Long-term Debt
14.96MUSDFY2025 · Dec 31, 2025Common Stock (Book)
21.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-97.40MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
140.75MUSDvs all stocks (USD)
52-Week Low
10.92USDUpdated Sep 28, 202652-Week High
24.59USDUpdated Sep 28, 202652-Week Change
41.56%vs all stocks
50-Day MA
20.49USDUpdated Sep 28, 2026200-Day MA
16.50USDUpdated Sep 28, 2026Avg 10-Day Volume
146.99KSharesUpdated Sep 28, 2026Avg 30-Day Volume
119.08KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-4.65USDUpdated Sep 28, 2026Other Income / Expense
-13.99MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -85.1%, lower than 95% of its Medical Devices peers (median 7.3%)Significant
Operating margin: -0.85Industry median: 0.07Industry P5: -0.73Peers compared: 102
Financial Health
Altman Z-Score 6.91: safe zoneNotable
Altman Z-Score: 6.91
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Cabaletta Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jiangsu GDK Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Surrozen, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
CapsoVision, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ocugen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule